[HTML][HTML] KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment
Background Monoclonal antibodies directed against the epidermal growth factor receptor
(EGFR) have been approved for the treatment of patients with metastatic colorectal
carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become
mandatory to chose the most appropriate therapy for these patients. Methodology/Principal
Findings In order to guarantee the possibility for mCRC patients to receive an high quality
KRAS testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and�…
(EGFR) have been approved for the treatment of patients with metastatic colorectal
carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become
mandatory to chose the most appropriate therapy for these patients. Methodology/Principal
Findings In order to guarantee the possibility for mCRC patients to receive an high quality
KRAS testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and�…
Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia
F Ciardiello, S Tejpar, N Normanno, D Mercadante…�- Targeted�…, 2011 - Springer
The mutation status of the KRAS gene in the tumors of patients with metastatic colorectal
cancer (mCRC) is a predictive biomarker for the efficacy of epidermal growth factor receptor
monoclonal antibody therapy. The establishment of KRAS mutation testing in this setting
represents a significant change to standard diagnostic procedures and a major advance in
the personalization of cancer care. Against a changing regulatory background, three cross-
sectional surveys of physicians in 14 countries in Europe, Latin America and Asia were�…
cancer (mCRC) is a predictive biomarker for the efficacy of epidermal growth factor receptor
monoclonal antibody therapy. The establishment of KRAS mutation testing in this setting
represents a significant change to standard diagnostic procedures and a major advance in
the personalization of cancer care. Against a changing regulatory background, three cross-
sectional surveys of physicians in 14 countries in Europe, Latin America and Asia were�…
Showing the best results for this search. See all results